Actively Recruiting
Multispectral Optoacoustic Imaging (MSOT) as Non-invasive Biomarker for Diagnosis and Monitoring of Neuromuscular Diseases (MSOT-NMD)
Led by Children's Hospital of Eastern Ontario · Updated on 2025-02-12
240
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are exploring whether Multispectral Optoacoustic Tomographs (MSOT) can effectively diagnose and monitor the progress of neuromuscular diseases in children. This observational study focuses on children from birth up to 18 years old who have confirmed or suspected neuromuscular diseases. The study aims to assess how MSOT imaging correlates with existing clinical, laboratory, and imaging data over about 36 months to better understand disease progression and the potential role of MSOT in patient care. The study involves taking MSOT scans of muscle regions to measure levels of hemo/myoglobin, collagen, lipid content, and oxygenation in affected children. These scans will be repeated every 6 to 12 months during the study period. No additional research procedures beyond MSOT imaging will be conducted. The study collects data from standard care alongside MSOT results to compare and track changes over time. Participants will have repeated MSOT imaging sessions spaced 6 to 12 months apart, for up to three years, depending on when they join the study. Researchers will analyze the quantitative signals from the MSOT scans, including collagen, lipid, and hemo/myoglobin proportions and oxygenation, and compare these with clinical assessments, laboratory tests, and patient-reported outcomes. The goal is to see how well MSOT can monitor neuromuscular disease progression in children while ensuring participant safety and comfort throughout the study.
CONDITIONS
Brief Title
MSOT as Non-invasive Biomarker for Diagnosis and Monitoring of Neuromuscular Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children from birth (infants born at term) up to 18 years of age
- Confirmed or suspected diagnosis of a neuromuscular disease by genetics, biopsy, or clinical exam
- Consent provided by guardian or authorized representative
You will not qualify if you...
- Diagnosis not consistent with a confirmed or suspected neuromuscular disease
- Active skin lesions such as infections or trauma
- Genetic skin disorders that cause skin lesions (e.g., epidermolysis bullosa)
- Medically unstable condition
- Tattoos on skin over the area to be scanned
- Missing consent form
- Any condition that the investigator feels compromises safety or data quality
- Medication causing increased light sensitivity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 36 months depending on enrollment time
Participants undergo multispectral optoacoustic tomography (MSOT) scans of muscle regions to measure hemo/myoglobin, collagen, and lipid content and oxygenation.
Repeated visits every 6 to 12 months
Trial Site Locations
Total: 1 location
1
CHEO
Ottawa, Ontario, Canada, K1H 8L1
Actively Recruiting
Research Team
H
Hanns Lochmuller, Dr.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here